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Dense	deposit	disease	(DDD)	is	a	severe	renal	disease	characterized	by	accumulation	of	electron-dense	material	
in	the	mesangium	and	glomerular	basement	membrane.	Previously,	DDD	has	been	associated	with	deficiency	
of	factor	H	(fH),	a	plasma	regulator	of	the	alternative	pathway	(AP)	of	complement	activation,	and	studies	in	
animal	models	have	linked	pathogenesis	to	the	massive	complement	factor	3	(C3)	activation	caused	by	this	
deficiency.	Here,	we	identified	a	unique	DDD	pedigree	that	associates	disease	with	a	mutation	in	the	C3	gene.	
Mutant	C3923ΔDG,	which	lacks	2	amino	acids,	could	not	be	cleaved	to	C3b	by	the	AP	C3-convertase	and	was	there-
fore	the	predominant	circulating	C3	protein	in	the	patients.	However,	upon	activation	to	C3b	by	proteases,	
or	to	C3(H2O)	by	spontaneous	thioester	hydrolysis,	C3923ΔDG	generated	an	active	AP	C3-convertase	that	was	
regulated	normally	by	decay	accelerating	factor	(DAF)	but	was	resistant	to	decay	by	fH.	Moreover,	activated	
C3b923ΔDG	and	C3(H2O)923ΔDG	were	resistant	to	proteolysis	by	factor	I	(fI)	in	the	presence	of	fH,	but	were	effi-
ciently	inactivated	in	the	presence	of	membrane	cofactor	protein	(MCP).	These	characteristics	cause	a	fluid	
phase–restricted	AP	dysregulation	in	the	patients	that	continuously	activated	and	consumed	C3	produced	by	
the	normal	C3	allele.	These	findings	expose	structural	requirements	in	C3	that	are	critical	for	recognition	of	
the	substrate	C3	by	the	AP	C3-convertase	and	for	the	regulatory	activities	of	fH,	DAF,	and	MCP,	all	of	which	
have	implications	for	therapeutic	developments.
Introduction
Complement is a major component of innate immunity, with cru-
cial roles in microbial killing, apoptotic cell clearance, immune 
complex handling, and modulation of adaptive immune respons-
es. Complement is activated by 3 independent activation path-
ways: the classical pathway (CP), the lectin pathway (LP), and the 
alternative pathway (AP). The critical steps in complement acti-
vation are the formation of unstable protease complexes, named 
complement factor 3–convertases (C3-convertases; specifically, 
C3bBb for AP and C4b2a for CP and LP), and the cleavage of C3 
by the convertases to generate C3b. Convertase-generated C3b 
can form more AP C3-convertase, providing exponential ampli-
fication to the initial activation. Binding of C3b to the C3-con-
vertases generates the C5-convertases with the capacity to bind 
and cleave C5, initiating formation of the lytic membrane attack 
complex (MAC). In contrast to the CP and the LP, whose activa-
tion is triggered by immune complexes and bacterial mannose 
groups, respectively, the AP is intrinsically activated. Spontaneous 
activation of C3 in plasma occurs through the tick-over mecha-
nism, which is initiated by hydrolysis of the internal C3 thioester 
to generate a C3b-like molecule, called C3i or C3(H2O). Activation 
of C3 also occurs by the continuous low rate cleavage of C3 to C3b 
by plasma proteases (1). Progression of complement activation 
results from the balance between the rate at which the initial acti-
vation is amplified and the rate at which C3b and the AP C3-con-
vertases are inactivated. Foreign substances on microbial patho-
gens (AP), antibodies (CP), or mannan (LP) disturb the balance 
in favor of amplification, causing target opsonization, leukocyte 
recruitment, inflammation, and cell lysis. In health, activation of 
C3 in plasma is kept at a very low level, and deposition of C3b 
and further activation of complement is limited to the surface 
of pathogens by multiple regulatory proteins, including factor H 
(fH), C4b-binding protein (C4BP), membrane cofactor protein 
(MCP), decay accelerating factor (DAF), complement receptor 1 
(CR1), and CD59. These control complement activation and 
avoid wasteful consumption of components by inactivating C3b 
or C4b, by dissociating the C3/C5-convertases, or by inhibiting 
membrane attack complex (MAC) formation (2–4).
Dense deposit disease (DDD) is a rare form of glomerulonephri-
tis that affects children and young adults and frequently develops 
into end-stage renal disease (ESRD; ref. 5). It is characterized by 
proliferation of mesangial and endothelial cells and by thickening 
of the peripheral capillary walls in the glomeruli (due to subendo-
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thelial and intramembranous dense deposits) that present a dou-
ble-contour appearance upon light microscopy. The morphologi-
cal hallmark of DDD is the presence of dense deposits within the 
glomerular basement membrane (GBM), as resolved by EM (6). The 
chemical composition of the dense deposits is largely unknown. 
Notably, IgG is absent from them and from other regions of the 
glomerulus, which excludes a role for immune complexes in their 
formation. DDD is associated with complement abnormalities that 
lead to intense deposition of C3 activation products in GBM and 
persistent reduction of C3 serum 
levels. Among the different factors 
associated with these complement 
abnormalities are the deficiency of 
the plasma AP regulator fH, as a 
result of mutations in the CFH gene 
or the presence of autoantibodies 
against fH, or the presence of auto-
antibodies against the C3-conver-
tase (C3 nephritic factors; C3Nef). 
Familial cases of DDD are excep-
tional. There are only approximately 
6 patients described in the literature 
in which deficiency of fH, either 
heterozygous or homozygous, is 
associated with the development of 
DDD. In all but one of these cases, 
the fH deficiency is caused by muta-
tions in CFH that result in trunca-
tions or amino acid substitutions 
that impair secretion of fH into 
circulation (7–9). The exception is 
the case of a CFH mutation in the 
complement regulatory region of 
fH that markedly reduced both the 
fI-mediated C3b cofactor activity 
and the AP C3-convertase decay-
accelerating activity of fH (10).
The severe dysregulation of the 
AP observed in DDD patients is 
consistent with data from animals 
presenting this renal phenotype. 
In the pig, fH deficiency results in 
a progressive glomerulonephritis, 
similar to human DDD, which 
leads to renal failure (11). Similarly, 
fH-knockout mice spontaneously 
develop a glomerulonephritis that 
also resembles human DDD (12). These fH-deficient animals have 
been very useful in demonstrating that the uncontrolled activa-
tion of C3 in plasma resulting from the lack of fH is essential for 
DDD development (12). The mouse model has also shown that 
the development of DDD requires fI, which suggests that the 
C3b, generated at high levels in the absence of fH, needs to be pro-
teolyzed to iC3b, C3c, and C3dg to produce this pathology (13). 
Furthermore, transplantation studies in the fH-deficient animals 
illustrate that glomerular C3 deposition derives from circulation 
Table 1
Progression of DDD patients
Patient	 Age	 Sex	 First	clinic	visit	 Current	kidney	 Time	to	 Biopsy	 Renal	 Graft
	 (yr)	 	 Age	 Cr	 Proteinuria	 Microhematuria	 status	 ESRD	 	 transplant	 recurrence
GN28 53 Female 28 yr 0.9 mg/dl 1.5 g/24 h Yes ESRD 7 yr Yes 3 YesA
III-1 26 Male 23 yr 1.4 mg/dl 0.4 g/24 h Yes FunctioningB – Yes No –
III-2 26 Male 16 yr 1.6 mg/dl 0.6 g/24 h Yes ESRDC 9 yr Yes No –
ATwo recurrences, and current transplant indicative of early stages of disease. BEarly stages of disease: persistent microscopic hematuria, 96 ml/min glo-
merular filtration rate. CPeritoneal dialysis.
Figure 1
Histology, immunofluorescence, and EM findings. The first kidney biopsy in GN28 was performed in 
1985. Although there was considerable variation in glomerular changes, there was remarkable simi-
larity in the light, immunofluorescence, and ultrastructural findings in the original kidney biopsy and 2 
allograft biopsies of GN28 and the kidney biopsies from III-1 and III-2. The characteristic histological 
lesion consisted of segmental mesangial hypercellularity with thickened, eosinophil-rich segments of 
basement membrane (A and B, arrows). The affected glomerular segments were PAS positive and 
reacted to trichrome stain (D, arrow). The affected tufts showed hypercellularity, leukocyte infiltration, 
and endothelial swelling. The mesangium showed variable expansion, matrix accumulation, and a lobu-
lar pattern (C and D, arrows). The main immunofluorescence findings were prominent and diffuse C3 
deposits, granular and nodular in some glomerular areas (G and J). Mild deposits of C1q, IgA, and IgM 
were also associated with these deposits (not shown). All biopsies showed similar ultrastructural altera-
tions consisting of a ribbon-like, osmiophilic deposit present in the GBM (E and I, red arrows). These 
deposits occasionally showed signs of dissolution with translucent areas (F, red arrows). The mesan-
gial areas showed increased mesangial matrix with electron-dense deposits (H and I, yellow arrows). 
Original magnification: ×400 (A, B, G, and J); ×500 (C and D); ×2,200 (E and F); ×5,500 (H); ×7,800 (I). 
Patient number is indicated within each panel.
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(13) and that the lytic pathway is not involved in the pathogenesis 
(14). Because fH regulates complement both in circulation and on 
cell surfaces, it is still debatable whether cell surface dysregulation 
plays a relevant role in DDD pathogenesis.
Here we report the first case to our knowledge of DDD caused 
by a mutation in the C3 gene, the functional characterization of 
which provided unique insights into DDD pathogenesis. Our 
findings provided conclusive evidence in humans that fluid 
phase–restricted AP dysregulation, which caused continuous 
generation of C3b in plasma, plays a major role in DDD patho-
genesis. Furthermore, analysis of this C3 mutation advanced our 
understanding of the activation and regulation of the AP C3-con-
vertase, providing useful information to unravel the structural 
requirements underlying the substrate recognition and regula-
tory activities of fH, DAF, and MCP.
Results
Familial case of DDD. We present the case of a 53-year-old woman 
(patient GN28; II-2) and her 26-year-old identical twin sons 
(referred to herein as III-1 and III-2). Their clinical presentation 
and development of disease are described in detail in Methods 
and summarized in Table 1. Biopsies taken from GN28, III-1, and 
III-2 illustrated similar findings by light and immunofluorescent 
microscopy that were consistent with a diagnosis of membranop-
roliferative glomerulonephritis (Figure 1). GN28 and III-2 reached 
ESRD after a prolonged period of progressive deterioration. III-1 
showed persistent microhematuria and limited proteinuria, but 
still preserved renal function. Nevertheless, the profound patho-
logical alterations found in the kidney biopsy from III-1 suggests 
that the patient will follow the same course to ESRD as his affect-
ed relatives. GN28 has been transplanted 3 times, with the disease 
recurring in all 3 allografts following the same course of disease 
as the original kidney.
Definitive diagnosis of DDD in GN28, III-2, and III-1 was estab-
lished on the basis of EM analyses in renal biopsies performed at 
early stages of the disease. These analyses illustrated an electron-
dense ribbon-like accumulation along the GBM and local electron-
dense deposits in the mesangium. The latter was the predominant 
lesion found in the kidney biopsy of III-1. This finding may explain 
why III-1 still preserves renal function and suggest that, as disease 
progresses, increasing electron-dense deposits will be found in the 
GBM in this patient. The findings by EM matched the histology 
and immunofluorescence results (Figure 1) and were also consis-
tent with the observations in biopsies from 2 allografts 
received by GN28 in which disease recurred.
Complement analysis in the 3 DDD-affected patients 
illustrated decreased levels of both C3 and fB (low-normal 
range) compared with their healthy relatives (Table 2), 
suggestive of activation through the AP. No activated 
C3 fragments were detected in plasma by Western blot, 
but terminal complement complex (TCC) levels were 
slightly elevated in GN28 and III-1 compared with 
controls (2.4 and 1.8 μg/ml, respectively; upper limit 
of normal, 1.24 μg/ml), indicating persistent low-grade 
C3 activation. Notably, although decreased, C3 levels 
in these patients were substantially higher than those 
usually found in DDD patients. Assays to identify 
C3Nef or anti-fH autoantibodies were negative. Levels 
of MCP on the surface of peripheral blood lympho-
cytes were normal in all 3 DDD patients.
Genetic analyses identify a C3 mutation associated with DDD. GN28, III-1, 
and III-2 were found to carry a mutation in heterozygosis in the C3 
gene (Figure 2). The mutation, c.2767_2774delACGGTG (C3923ΔDG) 
in exon 21, results in a mutated protein (C3923ΔDG) lacking 2 amino 
acids (Asp923 and Gly924) in the MG7 domain of C3. No muta-
tions were found in any other screened gene, including CFH, MCP, 
CFI, and CFB, and the C3923ΔDG mutation was not detected in more 
that 300 unrelated individuals. In our pedigree, C3923ΔDG was exclu-
sively present in all 3 DDD-affected members (Figure 2). It was asso-
Table 2
Complement data in DDD patients and relatives
Patient	 Relation	 C3	 C4	 fH	 fI	 fB	antigenic	 fB	hemolytic
GN28 Index case 94.2 26 21 100% 6.3 30%
I-1 Father 179 36 36 100% 25 100%
III-1 Son 94.4 22 22 100% 10 18%
III-2 Son 80.5 18 32 >100% 5.5 27%
II-3 Sister 114 26 43 >100% 34.6 100%
II-4 Brother 111 16 28 >100% 27 100%
Values are shown as mg/dl with the exception of fI and fB hemolytic, which are shown 
as percent of control. Reference ranges are as follows: C3, 80–177 mg/dl; C4, 14–47 
mg/dl; fH, 10–35 mg/dl; fB antigenic, 7.5–28 mg/dl. C3 and fB values for the 3 indi-
viduals carrying the C3 mutation c.2767_2774delACGGTG (p.923ΔDG) are shown 
in bold; sequencing of the CFH, CFB, CFI, and MCP genes did not identify additional 
mutations in these individuals.
Figure 2
Mutation in the C3 gene in a multiaffected DDD pedigree. Pedigree of 
index case GN28 is illustrated. Individuals are identified by numbers 
within each generation. Affected individuals are indicated by black sym-
bols. The twin brother III-1 (gray symbol) has not developed ESRD, but 
shows early signs of disease. II-5 is a sister of GN28 whose death at 
13 years of age was attributed to glomerulonephritis. C3 alleles carried 
by the individuals are shown. The chromatogram corresponding to the 
DNA sequence surrounding the mutated nucleotides in C3 is shown for 
GN28 and a control sample. The corresponding amino acid sequences 
for the WT and mutated alleles are indicated. Amino acid numbering 
refers to the translation start site (Met +1), and the nucleotide nomen-
clature refers to nucleotide A in the ATG translation initiation codon, 
according to Human Genome Variation Society recommendations for 
description of sequence variants.
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ciated with decreased C3 levels, probably secondary to C3 consump-
tion, as the mutation also associated with low fB levels (Table 2). 
This evidence of complement activation and the observation that 
C3923ΔDG was expressed normally in cells transfected with an expres-
sion plasmid in vitro (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI43343DS1) suggest 
that C3923ΔDG is likely a gain-of-function mutation causing constitu-
tive activation of complement. C3 mutation screening in all DDD 
patients in our cohort (n = 8) failed to identify additional patients 
carrying the C3923ΔDG mutation or additional C3 mutations.
The C3923ΔDG mutation deletes 2 amino acids within MG7 in the 
polypeptide linking the MG7 and CUB domains. The deletion 
shortens the distance between the MG7 and CUB domains, likely 
displacing the upstream and downstream amino acids from their 
original positions. It is likely that these structural changes alter the 
function of C3 in a way that results in DDD. To test this possibility, 
we purified the mutant C3923ΔDG protein and assessed its function.
C3923ΔDG is the major circulating C3 protein in the DDD patients. C3 was 
purified to homogeneity from EDTA-plasma obtained from GN28, 
III-1, III-2, and normal controls (Supplemental Methods and Sup-
plemental Figure 2). Interestingly, when mixed with fB and fD in 
the presence of Mg2+, the C3 purified from GN28, III-1, and III-2 
was largely resistant to C3b generation (Figure 3). The presence of 
potential inhibitory contaminants in the C3 preparations from 
GN28, III-1, and III-2 was ruled out by showing that in a C3 prepa-
ration containing equal amounts of normal control C3 and mutant 
C3 purified from GN28, approximately half the C3 was cleaved, cor-
responding to the amount of normal protein present (Figure 3).
Separation of C3923ΔDG from C3WT in the C3 preparation from 
GN28, III-1, and III-2 was achieved using a Mono S HR 1.6/5 cation 
exchange column (GE Healthcare) with a pH 6–8 gradient (20 mM 
Na/K phosphate, 40 mM NaCl). In this chromatographic setting, 
C3 from GN28 produced 2 well-separated peaks, the first comigrat-
ing with the single C3 peak obtained from a similar experiment 
with a C3 preparation from a control individual (Figure 4A). Pro-
teomic analysis of the C3 protein contained in each peak confirmed 
that the second peak corresponded to pure C3923ΔDG mutant pro-
tein (Figure 4B). EM analyses of the C3WT and C3923ΔDG proteins 
purified from the GN28 plasma resulted in 3D structures that were 
indistinguishable at the resolution level of this technique (approxi-
mately 25Å), which indicates that the deletion of the 2 amino acids 
in the C3923ΔDG mutant did not cause gross changes in the structure 
of the C3 protein. The structures also demonstrated that C3923ΔDG 
circulates in plasma mainly in the native (nonactivated) C3 con-
formation (Supplemental Figure 3). Similar proportions (approxi-
mately 1:2) of C3WT and C3923ΔDG were present in the plasma sam-
ples from the 3 C3923ΔDG mutation carriers (Table 3).
When purified C3923ΔDG was incubated with fB and fD in the pres-
ence of Mg2+, no generation of C3b was observed despite cleavage 
of fB and generation of Bb; conversely, C3WT was completely con-
verted to C3b under these conditions (Figure 5A). To confirm that 
C3923ΔDG could not be activated to C3b by the AP C3-convertase, we 
performed surface plasmon resonance (SPR; Biacore) experiments 
with the C3923ΔDG and C3WT proteins purified from GN28 and 
healthy controls, respectively. We immobilized a small amount of 
C3bWT onto a Biacore chip and generated a nidus of convertase with 
fB and fD. Then, either C3WT or C3923ΔDG was flowed over the sur-
face as substrate of this convertase; activation of C3WT or C3923ΔDG 
exposes the thioester and results in accumulation of protein onto 
the Biacore chip via a covalent link. In agreement with previous 
experiments, when C3923ΔDG was flowed, no protein deposited on 
the surface, in contrast to the deposition evident when C3WT was 
flowed (Figure 5B), which indicated that the mutant C3923ΔDG was 
not converted into nascent C3b by the AP C3-convertase. As a 
whole, these experiments demonstrated that C3923ΔDG is the major 
C3 protein circulating in the plasma of the DDD patients, because 
the constitutive AP activation present in these individuals exclu-
sively consumed the C3WT produced by the normal C3 allele.
C3923ΔDG activates to C3(H2O)923ΔDG and generates an active AP C3-con-
vertase. We next sought to determine why C3WT produced by the 
normal allele was consumed in C3923ΔDG carriers. C3923ΔDG was not 
converted to C3b when mixed with fB and fD in the presence of 
Mg2+ (Figure 5A). However, in these experiments, fB was complete-
ly consumed to Bb, which suggests that the preparations contain 
some hydrolyzed C3923ΔDG that binds and activates fB and is there-
fore able to form an active AP C3-convertase. We have previously 
Figure 3
Total C3 from GN28 is only partially cleaved to C3b in the presence of fB 
and fD. Coomassie-stained gels correspond to the SDS-PAGE analyses 
of C3 purified from GN28 and a normal control after incubation with fB 
and fD. The experiment was repeated twice with identical results. Top: 
C3 purified from normal individuals was rapidly and completely activated 
to C3b (determined by cleavage of the C3 α chain) in the presence of 
fB and fD. This activation correlated with consumption of fB and the 
appearance of the Bb fragment, indicating formation of the AP C3-con-
vertase. Middle: Same experiment with C3 purified from GN28. Despite 
formation of the AP C3-convertase (demonstrated by consumption of 
fB and generation of the Bb fragment), only a small proportion of the 
C3 was activated to C3b. This suggests that C3 purified from the GN28 
plasma contains 2 different C3 forms (WT and mutant protein), and that 
only C3WT is cleaved to C3b. Bottom: To rule out the presence of inhibi-
tors in the C3 preparation from the GN28 plasma, a mixing experiment 
(equivalent amounts of control and GN28 C3) showed that addition of fB 
and fD caused activation of 50% of the C3, likely C3WT.
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used SPR to monitor C3bBb formation and dissociation in real 
time (15). Hydrolyzed C3WT (1,224 RU) or C3923ΔDG (1,067 RU) was 
thiol-coupled to a CM5 chip, and convertase formation was ana-
lyzed by flowing fB (270 to 17 nM) over the surface in the presence 
of fD (43 nM). Kinetics were analyzed according to the Langmuir 
1:1 binding model, and convertase formation by C3(H2O)923ΔDG and 
C3(H2O)WT was found to be comparable (Figure 6A). We tested next 
whether the AP C3-convertase generated from C3(H2O)923ΔDG was 
capable of activating C3WT. We generated a C3-convertase immobi-
lized onto a Biacore chip using either C3(H2O)923ΔDG or C3(H2O)WT 
and flowed C3WT over the surface. The mutant C3-convertase was 
able to activate C3WT, although it showed approximately 50% of the 
activity of the WT AP C3-convertase (Figure 6B).
C3(H2O)923ΔDG generates a C3-convertase resistant to fH inactivation. We 
have shown here that C3923ΔDG activated spontaneously and that 
the activated C3(H2O)923ΔDG interacted normally with fB to gener-
ate an active C3-convertase. To determine whether the mutant C3-
convertase is regulated efficiently by fH, we immobilized C3(H2O)WT 
or C3(H2O)923ΔDG as described above and flowed fH (1 μM to 8 nM) 
over the surface. The affinity of C3(H2O)923ΔDG for fH was reduced 
compared with C3(H2O)WT (Figure 7A). In complemen-
tary experiments, we found that this decreased binding 
impaired the capacity of fH to both decay the convertase 
generated from C3(H2O)923ΔDG (Figure 7B) and act as a 
cofactor in the fI-mediated inactivation of C3(H2O)923ΔDG 
(Figure 7D). In contrast to the results obtained with fH, 
the C3-convertase generated from C3(H2O)923ΔDG was 
efficiently decayed by DAF (Figure 7C).
MCP, but not fH, catalyzes fI cleavage of C3b923ΔDG and 
C3(H2O)923ΔDG. We generated large amounts of C3b923ΔDG 
using trypsin and C3(H2O)923ΔDG using 0.33 M potas-
sium isothiocyanate, and used them to test the cofac-
tor activities of fH and MCP for fI-mediated proteolysis. 
In agreement with our findings described above, 
C3(H2O)923ΔDG interacted with and consumed fB in the 
presence of fD and Mg2+; trypsin-generated C3b923ΔDG 
behaved similarly (Supplemental Figure 4). The trypsin-
generated C3b923ΔDG also formed an active AP C3-con-
vertase on a Biacore chip, although it showed less than 
5% the activity of the AP C3-convertase generated with 
C3bWT (data not shown). Addition of C3b923ΔDG to nor-
mal human sera activated complement and consumed 
C3 (Figure 8), which indicated that, despite its low activ-
ity, the mutant convertase was able to dysregulate the 
AP, most likely because C3b923ΔDG is resistant to inactiva-
tion by fI and fH. As expected, C3bWT had some capac-
ity to activate C3 in normal serum, but this was much 
reduced compared with C3b923ΔDG.
In order to confirm the differences in cofactor activ-
ity of fH and MCP in the fI-mediated proteolysis of 
C3b923ΔDG and C3(H2O)923ΔDG, we performed a fluid 
phase assay. Identical amounts of C3b923ΔDG and 
C3bWT were added to purified fH (or MCP) in the 
presence of fI and incubated for 1, 2, 5, 10, 15, and 30 
minutes at 37°C. C3b923ΔDG was resistant to inactiva-
tion by fI in the presence of fH, but was inactivated by 
fI with soluble MCP (sMCP) at the same rate as C3bWT 
(Figure 9). The same cofactor selectivity was found for 
C3(H2O)923ΔDG (Figure 10).
Discussion
Here we report the identification and functional characterization 
of C3923ΔDG, which we believe to be the first C3 mutation associ-
ated with DDD. The functional consequences of this mutation 
are remarkable, providing fundamental insights into both DDD 
pathogenesis and structural aspects of AP C3-convertase control 
Figure 4
Purification of the mutant allele C3923ΔDG. (A) C3923ΔDG and C3WT were separated as 
described in Methods. The elution profiles of this chromatographic separation of C3 
prepared from control plasma (dotted line) and from GN28 plasma (solid line) are 
indicated. (B) The identity of the C3 variants was determined by mass spectrometry, 
as described in Methods. The minor C3WT peak showed some contamination of the 
major C3923ΔDG mutant protein (asterisk). Exp, expected; Obs, observed.
Table 3
C3 proteins in the plasma of C3923ΔDG mutation carriers
Patient	 Allele	 C3	(mg/dl)	 Percent	total	C3
GN28 C3WT 26 27%
GN28 C3923ΔDG 68 73%
III-1 C3WT 31 32%
III-1 C3923ΔDG 64 68%
III-2 C3WT 28 35%
III-2 C3923ΔDG 52 65%
Total C3 levels were 94 mg/dl in GN28, 95 mg/dl in III-1, and 80 mg/dl 
in III-2.
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by the complement regulatory proteins fH, DAF, and MCP. The 
C3923ΔDG mutation was found in heterozygosis in 2 DDD patients 
and in a relative in the early stages of the disease who present 
decreased levels of C3 and constitutive activation of the comple-
ment AP. C3923ΔDG causes the deletion of 2 amino acids within 
MG7, but this does not affect C3 expression or its overall struc-
ture. The mutant C3923ΔDG protein was the predominant C3 pro-
tein in the plasma of C3923ΔDG carriers, where it circulated in the 
form of native, nonactivated, C3. As a consequence of the muta-
tion, the mutant C3923ΔDG could not be activated to C3b by the AP 
C3-convertase. This explains why levels of C3 in the DDD patients 
carrying C3923ΔDG were reduced only by 50%, in contrast to the 
complete C3 consumption found in most DDD patients. Crucial-
ly, we demonstrate that the C3923ΔDG mutant could be activated 
to C3b923ΔDG by proteases, or to C3(H2O)923ΔDG by the spontane-
ous hydrolysis of the thioester, and both generated an active AP 
C3-convertase that cleaved WT C3 to generate C3b. Moreover, 
these mutant C3-convertases were resistant to inactivation by fH, 
and neither C3b923ΔDG nor C3(H2O)923ΔDG could be proteolyzed by 
fI in the presence of fH.
Figure 5
Resistance of purified C3923ΔDG to cleavage by the AP C3-convertase. (A) C3923ΔDG and C3WT were purified to homogeneity and tested for their 
capacity to be cleaved to C3b in the presence of fB and fD; only the α chain of C3WT was cleaved. Of note, C3923ΔDG consumed fB, illustrating 
formation of a AP C3-convertase. This experiment was repeated twice. Lanes were run on the same gel but were noncontiguous (white lines). (B) 
C3WT (1,000 RU) was immobilized via amine coupling to a CM5 Biacore chip. Convertase was formed by flowing fB (2.6 μM) and fD (43 nM) in 
the presence of Mg2+. At the indicated time (arrows), C3WT (gray line) or C3923ΔDG (black line) was flowed over the surface. Remaining convertase 
was decayed using sDAF, and deposition of nascent C3b was measured. Resp. diff., response difference.
Figure 6
AP C3-convertase formation by C3923ΔDG and C3WT. (A) Hydrolyzed C3WT (1,224 RU) or C3923ΔDG (1,067 RU) was thiol-coupled to a CM5 Biacore chip. 
Convertase formation was analyzed by flowing fB (270 to 17 nM) over the surface in the presence of fD (43 nM). Kinetics were analyzed according to 
the Langmuir 1:1 binding model. Convertase formation by mutant C3923ΔDG and C3(H2O)WT, measured as KD, was comparable. (B) Hydrolyzed C3WT 
(1,640 RU) or C3923ΔDG (2,000 RU) was thiol-coupled to a CM5 Biacore chip. fB and fD were flowed over the surfaces to form either C3(H2O)WTBb 
(black line) or C3(H2O)923ΔDGBb (gray line). C3WT was injected over the surface, where it was cleaved to nascent C3b and deposited on the surface 
via the thioester group. Remaining convertase after deposition was decayed using sDAF, and bound C3b was measured as change from baseline.
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These altered functions provide a pathogenic mechanism that 
explains the development of DDD in our patients. C3923ΔDG cir-
culates in the plasma of the patients at stable and high levels 
and constantly produces activated C3 molecules by the tick-over 
mechanism (or through non–complement-mediated proteolysis), 
which cannot be inactivated by fH in plasma. In turn, the activated 
mutant C3 molecules generate active AP C3-convertases that can-
not be regulated by fH, resulting in complement dysregulation in 
the fluid phase and substantial consumption of the WT C3 pro-
tein and fB in these heterozygote DDD patients.
In contrast to the situation in plasma, in which AP comple-
ment regulation depends almost exclusively on fH, on cell sur-
faces, complement regulators like MCP and DAF efficiently 
regulate the generation and stability of the AP C3-convertase. 
Our demonstration that the AP C3-convertases generated from 
the mutant C3923ΔDG were decayed normally by DAF, and that 
the activated molecules C3b923ΔDG and C3(H2O)923ΔDG were effi-
ciently inactivated by fI in the presence of MCP, is most relevant 
to DDD pathogenesis. Thus, not only is C3923ΔDG resistant to 
cleavage to C3b by the AP C3-convertases, limiting the deposi-
tion of C3923ΔDG on the cell surface to the very few molecules 
that may spontaneously activate in its vicinity, but also these few 
mutant molecules will be efficiently controlled by DAF and MCP 
on the cell membranes. These data provide conclusive evidence 
that DDD in our patients results exclusively from a fluid phase–
restricted AP dysregulation.
C3 is the most abundant protein of the complement system 
(~1.3 mg/ml). The structure of native C3 has been resolved at atom-
ic resolution using X-ray crystallography (16) and reveals an intri-
cate arrangement of 13 domains, including a core of 8 homologous 
macroglobulin domains forming a ring; a TED domain, linked to 
this ring by a CUB domain, that contains the reactive thioester; 
and the C345C domain, which participates in the interaction with 
Figure 7
Reduced affinity of fH for hydrolyzed C3923ΔDG impairs both decay of the mutant C3-convertase and fI-mediated inactivation of hydrolyzed 
C3923ΔDG. (A) Hydrolyzed C3WT (1,224 RU) or C3923ΔDG (1,067 RU) were thiol-coupled to a CM5 Biacore chip. The affinity for native fH was ana-
lyzed by flowing fH (1 μM to 8 nM) over the surface and determined by steady-state analysis. The affinity of fH for C3(H2O)923ΔDG was reduced 
2-fold compared with C3WT. Values are mean ± SD of 3 determinations. (B) Convertase was formed on each hydrolyzed C3 surface by flowing 
fB and fD. After a period of natural decay, fH (0.9 μM) was injected for 60 seconds. Convertase formed by C3(H2O)WT (gray line) was efficiently 
decayed by fH, whereas the C3(H2O)923ΔDG convertase (black line) was inefficiently decayed. Binding (RU) of fH to the surface in the absence of 
the convertase was subtracted; curves illustrate decay of Bb. (C) In contrast, mutant convertase was efficiently decayed by DAF (0.4 μM). (D) 
Hydrolyzed C3WT or C3923ΔDG was thiol-coupled to a CM5 Biacore chip. Initial formation of convertase on each surface was assessed by flowing fB 
and fD (black line). After complete decay of the convertase, fH (0.33 μM) and fI (0.11 μM) were flowed across the surface for 5 minutes at 5 μl/min. 
Convertase was then formed again (gray lines) using identical conditions. Enzyme formation by C3(H2O)WT convertase was reduced 50% by 
fI/fH treatment, whereas enzyme formation from C3(H2O)923ΔDG convertase was hardly affected.
Figure 8
C3b923ΔDG activates C3 cleavage in normal human serum. The capacity 
of C3b923ΔDG and C3bWT to activate C3 in normal serum was tested by 
incubating 180 ng of each C3b with a 1:20 dilution of normal serum at 
37°C in AP buffer (5 mM Veronal; 150 mM NaCl; 7 mM MgCl2; 10 mM 
EGTA, pH 7.4). Samples (5 μl) were taken at the indicated times and 
loaded into a 10% SDS-PAGE. C3 activation was measured by the 
appearance of the 43-kDa fragment of C3 α′ chain, as detected by 
Western blot. The α′ 43 band of iC3b is shown for comparison.
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fB. Cleavage of C3 into C3b, or generation of C3(H2O), induces 
a huge conformational displacement of the TED domain, expos-
ing the reactive group. In addition, this conformational change 
generates binding sites for a number of molecules, including the 
AP convertase component fB and the complement regulators fH, 
DAF, and MCP (reviewed in ref. 17). Because the 2–amino acid 
deletion caused by the C3923ΔDG mutation lies within, and likely 
alters, these interaction surfaces (Supplemental Figure 5), we ana-
lyzed the interaction of C3b923ΔDG and C3(H2O)923ΔDG with fB, fH, 
DAF, and MCP. Our data showed no differences in 
the assembly and stability of the AP C3-convertase 
formed by WT and mutant C3, which indicates that 
the mutation does not substantially modify the sur-
faces interacting with fB. In contrast, the C3923ΔDG 
mutant showed a differential sensitivity to regula-
tion by fH, DAF, and MCP, clearly illustrating that 
there are distinct structural requirements underly-
ing the decay regulatory activities of fH and DAF, as 
well as the fI cofactor activities of fH and MCP.
The crystal structure of the complex between C3b 
and a truncated form of fH has shown that the first 
4 short consensus repeat domains (SCRs) of fH, 
responsible for its decay-accelerating and fI cofac-
tor activities, bind C3b in an extended configura-
tion, which partially overlaps the site involved in 
the interaction with fB in the initial steps of the AP 
convertase assembly (Supplemental Figure 5 and 
refs. 18–20). These structural data explain previous 
mutagenesis experiments and functional analyses 
of disease-associated mutations indicating that fH 
competes with fB in the formation of the C3bB pro-
convertase and interferes with the positioning of 
the Bb fragment, destabilizing C3bBb, the active AP 
C3-convertase. Our data support the hypothesis that 
the C3923ΔDG mutation specifically alters the site of 
interaction of fH SCR1–SCR2 with C3b. Because 
the mutation does not affect the function of DAF, 
these data also support early mutagenesis results indicating that 
DAF and fH have distinct structural requirements for their decay 
activity and that whereas fH SCR1–SCR2 interacts with C3b, DAF 
SCR1–SCR2 interacts primarily with Bb (15, 21, 22).
fH and MCP are vital cofactors for fI-mediated inactivation 
of C3b in the CUB domain, which yields the inactive iC3b spe-
cies. As with the differential decay acceleration of the mutant 
C3923ΔDG convertase by DAF and fH, the C3923ΔDG mutation 
affected cofactor activity of fH, but not of MCP, which indicates 
Figure 9
C3b923ΔDG is inactivated by fI and 
MCP, but not by fH and fI. Activat-
ed C3bWT or C3b923ΔDG was incu-
bated with fI and either fH (A) or 
sMCP (B). Cleavage of the α′ chain 
was indicated by generation of the 
α65 and α43 products. The experi-
ment was repeated twice with 
identical results.
Figure 10
C3(H2O)923ΔDG is resistant to inactivation by fI in the presence of fH, but not in the pres-
ence of sMCP. Hydrolyzed C3923ΔDG or C3WT were incubated with fI and either fH (A) 
or sMCP (B). Cleavage of the α′ chain was indicated by generation of the α74 and α43 
products. The experiment was repeated twice.
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that fH and MCP have distinct structural requirements of C3b 
for their function. In agreement with early work (21, 22), our 
data indicate that the interaction between fH SCR1–SCR2 and 
C3b is critical for its cofactor activity, whereas for MCP, the 
interaction with this site in C3b does not substantially contrib-
ute to its cofactor activity (23, 24).
C3923ΔDG could not be cleaved by the AP C3-convertase. Since the 
mutation locates distant to the AP C3-convertase cleavage site, 
one possibility is that it alters a region in C3 recognized by the 
substrate binding site in the C3b component of the AP C3-con-
vertase. It was recently proposed that this interaction between C3 
and C3b involves a large area on the same face of C3 (or C3b) that 
includes the domains MG3, MG4–5, and MG6−8 (25). Interest-
ingly, this area of C3 overlaps with binding sites for the inhibitors 
compstatin (26), CRIg (27), and antibody S77 (28), which block 
substrate binding to the C3-convertase. In fact, the C3923ΔDG muta-
tion coincides with the interaction site of S77, which involves the 
His897 amino acid residue in C3 (28). It is therefore very likely 
that the mutant C3923ΔDG could not be cleaved by the C3bBb con-
vertase because the sequence on C3 recognized by the highly spe-
cific substrate binding site located on the C3b component of the 
C3bBb convertase has been lost (Supplemental Figure 6). These 
data may also explain why the AP C3-convertase generated by the 
mutant C3b923ΔDG showed minimal activity compared with that 
generated by C3WT. In this context, however, it is remarkable that 
C3(H2O)923ΔDG built a relatively normal AP C3-convertase that effi-
ciently cleaved C3WT (Figure 6). This suggests that the structural 
requirements for the substrate (C3) recognition in C3b are influ-
enced by the presence of the C3a domain in C3(H2O). This hypoth-
esis, together with earlier data by Bexborn et al. (29) showing that 
the C3(H2O)Bb convertase is more resistant to inactivation by fH 
and fI, warrant further research — out of the scope of the present 
study — into the role and specific properties of the C3-convertase 
generated through the tick-over mechanism.
In conclusion, our identification and functional characteriza-
tion of the C3923ΔDG mutation provided fundamental insights 
into both the pathogenic mechanisms underlying DDD and the 
structural aspects of substrate recognition and regulation of the 
C3bBb convertase. Previous studies have shown that the control of 
complement activation is impaired in DDD patients and that dys-
regulation of the complement system may result from decreased 
activity of the complement regulatory protein fH. We showed 
here that fluid phase complement dysregulation may also be a 
consequence of mutations in the AP C3-convertase components 
making the convertase resistant to inactivation by fH. This has 
important therapeutic implications. Although replacement thera-
pies providing fH may be successful in the former case, they will 
be ineffective if C3 is mutated. In this latter case, however, patients 
may benefit from therapies involving soluble forms of membrane-
associated regulators like MCP. Recently, several mutations and 
polymorphisms in the genes encoding fH, MCP, and DAF have 
been associated with a number of disorders involving complement 
dysregulation (30). Interestingly, the functional characterization 
of these genetic variations and laboratory mutants reveals that, 
despite their common evolutionary origin and overlapping func-
tions, fH, MCP, and DAF have distinct structural requirements in 
their regulatory activities. The structural characterization of the 
C3923ΔDG mutant may help to delineate the interaction sites for the 
different complement regulators in C3b, which, again, may have 
important implications in the design of therapeutic agents.
Methods
Patients. GN28 (II-2), a 53-year-old woman, presented with hypertension, 
microscopic hematuria and proteinuria at age 25 years, during the third 
trimester of her first and only identical twin pregnancy. She had an epi-
sode of nephritis at age 7. After 2 years of persistent microhematuria, 
proteinuria rising to 1.5 g/day and plasma creatinine (Cr) of 0.9 mg/dl, 
a renal biopsy was performed that illustrated segmental mesangial 
hypercellularity with thickened, brightly eosinophilic segments of base-
ment membrane (Figure 1, A–D). There were prominent and diffuse C3 
deposits, granular and nodular in some glomerular areas (Figure 1G). 
Transmission EM demonstrated the presence of a ribbon-like, osmio-
philic deposit in the GBM (Figure 1, E and F). Mild deposits of C1q, IgA, 
and IgM were also present. Anti-nuclear (ANA) and anti-DNA antibodies 
were negative. Levels of C4 were normal, whereas C3 and fB were in the 
low-normal range. During the following 6 years, renal function progres-
sively declined with proteinuria, reaching a nephrotic range of 7 g/d. 
In 1991, at age 35, the patient started dialysis. In 1992, she received a 
cadaver kidney allograft that lasted until 1997. Interestingly, beginning 
the second month after transplant, the patient presented with hyper-
tension, microhematuria, and progressive proteinuria that reached 
nephrotic range in the fourth posttransplant year. The patient went 
back to dialysis the following year. In 1998, she received a second cadaver 
kidney allograft that lasted until 2003, following a similar period of pro-
gressive renal insufficiency and proteinuria, this time beginning 3 years 
after transplantation. Biopsies taken from this and the previous kid-
ney allograft, illustrated microscopic findings similar to those found in 
the original kidney. In 2006, the patient received a third cadaver kidney 
allograft that is still functioning. However, the patient presents micro-
hematuria, proteinuria, and progressive renal insufficiency that is accel-
erating in the third posttransplant year.
III-2, 26 years old, is one of the identical twin sons of GN28. At age 2, 
coincident with an episode of fever, he presented with microhematuria. 
In 1999 (age 16 years), he was admitted to hospital because of hyperurice-
mia (9.1 mg/dl), showing proteinuria of 1.5 g/d, microhematuria (10–25 
erythrocytes/field), and Cr of 1.4 mg/dl, corresponding to a creatinine 
clearance (CCr) of 73 ml/min. Like GN28, levels of C4 were normal, but 
C3 and fB were in the low-normal range. 5 years later (age 21 years), renal 
function started to decline with a Cr of 2 mg/dl, CCr of 46 ml/min, pro-
teinuria of 1.1 mg/dl, and persistent microhematuria. Another 6 months 
later, Cr and CCr rose to 3 mg/dl and 33 ml/min, respectively. Renal biop-
sy at this time showed membranoproliferative glomerulonephritis with 
intense C3 deposits similar to those observed in the kidney biopsies of 
GN28. 9 years later, his renal function deteriorated to ESRD. The patient 
is currently on peritoneal dialysis.
III-1, 26 years old, is one of the identical twin sons of GN28. Despite 
microhematuria being evident in occasional follow-up visits, the patient 
was not available for assessment until 2006 (age 23 years). In his first visit 
to the nephrologist, he showed hyperuricemia of 8.5 mg/dl, Cr of 1.4 mg/dl 
with a CCr of 105 ml/min, proteinuria of 0.4 mg/dl, and microhematuria 
(12 erythrocytes/field). These values were slightly increased in 2010 (Cr, 
1.6 mg/dl; CCr, 96 ml/min; proteinuria of 0.5 mg/dl), suggestive of pro-
gressive deterioration. As with the affected relatives, levels of C4 were nor-
mal, whereas C3 and fB were in the low-normal range. Renal biopsy showed 
membranoproliferative glomerulonephritis with intense mesangial C3 
deposits and very limited C3 deposition within the GBM. This finding is in 
contrast with the kidney biopsies from GN28 and III-2, which may explain 
why the patient still preserves renal function.
The studies described herein received IRB approval (Comision de 
Bioetica, Consejo Superior de Investigaciones Científicas, Madrid, Spain). 
Patients and their relatives gave their informed consent.
Downloaded on February 24, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43343
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 10   October 2010 3711
Complement analysis. Plasma or serum C3 and C4 levels were measured 
using standard nephelometric assays (Siemens). fH, fI, and fB levels were 
measured by sandwich ELISA as previously described (31–33). Anti-fH and 
C3Nef autoantibodies were detected as described previously (34, 35). Their 
concentrations in plasma were calculated by reference to the appropriate 
calibration curve prepared from purified proteins and expressed as mg/dl 
plasma, or percent of control for fI concentration. fB hemolytic activity was 
tested according to Lesavre et al. (36).
Mutation screening and genotyping. Genomic DNA was obtained from 
peripheral blood mononuclear cells using Puregene Blood Core kit B 
(QIAGEN) according to the manufacturer’s instructions. Each exon of the 
CFH, MCP, CFI, and CFB genes was amplified from genomic DNA using 
specific primers derived from the 5′ and 3′ intronic sequences, as described 
previously (37–39). Exons of the C3 gene were amplified from genomic 
DNA using the primers described in Supplemental Table 1. Automatic 
sequencing was performed in an ABI 3730 sequencer using a dye termina-
tor cycle sequencing kit (Applied Biosystems).
Biosensor analysis. To measure affinity of fB or fH for C3, hydrolyzed 
C3WT (1,224 RU) or C3923ΔDG (1,067 RU) was thiol-coupled to a CM5 
Biacore chip according to the manufacturer’s instructions (ligand thiol 
coupling method; GE Healthcare). Convertase formation was analyzed 
by flowing fB (270 nM to 17 nM) over the surface in the presence of fD 
(1 μg/ml; Comptech) in HBS/Mg/P (10 mM HEPES, pH 7.4; 150 mM 
NaCl; 1 mM MgCl2; and 0.005% surfactant-P20). The affinity for native 
fH was similarly analyzed by flowing fH (1 μM to 8 nM) over the sur-
face. All samples were injected using the Kinject command, flowed at 
30 μl/min, and analyzed at 25°C. Kinetic experiments were carried out 
on a Biacore T100 (GE Healthcare); fB affinity was calculated according 
to the Langmuir 1:1 binding model, and fH affinity was determined by 
steady-state analysis (Biaevaluation v1.1).
In order to assess fH-mediated decay of the convertases, hydrolyzed C3WT 
or C3923ΔDG was thiol-coupled to the chip, convertase was formed on each 
surface by flowing fB and fD, and, after 60 seconds of natural decay, either 
native fH or sDAF was injected for 60 seconds. The same injection of fH 
was performed in the absence of convertase formation, and the binding 
curve was subtracted to control for fH binding to the surface; the resultant 
curve was therefore representative of Bb decay only. Accelerated decay was 
evident by the sharp increase in the dissociation rate.
Cofactor activity was assessed by flowing fH (0.33 μM) and fI (0.11 μM) 
across the surface for 5 minutes at 5 μl/min. The capacity of C3(H2O) on 
the surface to form a convertase was assessed before and after fH and fI 
injection by flowing fB and fD; decrease in convertase formation indicated 
cleavage of C3(H2O) to iC3(H2O).
To determine whether convertase formed by C3(H2O)923ΔDG was active 
and able to cleave C3WT to C3b, hydrolyzed C3 was thiol-coupled to a 
CM5 Biacore chip on a Biacore 3000 (GE Healthcare), and convertase was 
formed by flowing fB and fD in HBS/Mg/P for 120 seconds. After a short 
dissociation period (approximately 120 seconds), C3WT was flowed over 
the surface (22 μM) for 240 seconds, Bb was decayed using sDAF, and C3b 
bound to the surface was assessed by the change in baseline as indicated. 
To determine whether C3923ΔDG was a substrate for the C3WT convertase, 
C3bWT (1,000 RU) was coupled to the surface via the thioester as previously 
described (15). Convertase was formed in HBS/Mg/P by flowing fB (2.7 μM) 
and fD (43 nM) for 120 seconds. Following a period of dissociation, 
C3923ΔDG was injected at a concentration of 0.4 μM at 10 μl/min for 120 
seconds. Remaining convertase was decayed using 0.4 μM sDAF. The con-
vertase was formed again as described above, and 0.4 μM C3WT was simi-
larly flowed over the surface. Cleavage and deposition of C3b was assessed 
by change in the baseline after regeneration.
Activation of C3 in fluid phase. Purified C3 (2.7 μM), fB (0.5 μM), and fD 
(0.17 μM) in 20 mM sodium phosphate buffer (pH 7), 40 mM NaCl, and 2 mM 
MgCl2 were incubated in a water bath at 37°C. Aliquots of 5 μl were extract-
ed from the mix at 0, 0.5, 1, 2, 4, 8, and 16 minutes; mixed with SDS-PAGE 
sample buffer (2% SDS, 62.5 mM Tris, 10% glycerol, and 0.75% bromophenol 
blue) to stop the reaction; and loaded into a 10% reducing SDS-PAGE gel. 
The gels were stained using Coomassie brilliant blue R-250 (BioRad).
fH and sMCP cofactor activity for fI-mediated proteolysis of fluid phase C3b. The 
fluid-phase cofactor activities of fH and sMCP were determined in a C3b 
proteolytic assay using purified proteins. In brief, C3b, fH or sMCP, and fI 
were mixed in 10 mM HEPES (pH 7.5), 150 mM NaCl, and 0.02% Tween 20. 
Final concentrations in one set were 1.9 μM C3b, 0.2 μM fI, and 0.46 μM 
sMCP, and in the other set 0.42 μM C3b, 43 nM fI, and 47 nM fH. Molari-
ties were calculated using the following masses: fI, 88 kDa; C3, 185 kDa; 
fH, 155 kDa; fD, 23 kDa; fB, 93 kDa; sDAF, 28 kDa; sMCP, 28 kDa. Mix-
tures were incubated at 37°C in a water bath, and 6-μl aliquots were col-
lected at 0, 1, 2, 5, 10, 15, 30, and 60 minutes. The reaction was stopped 
by the addition of 5 μl SDS sample buffer. Samples were analyzed in 10% 
SDS-PAGE under reducing conditions. Gels were stained with Coomassie 
brilliant blue R-250 (BioRad), and proteolysis of C3b was determined by 
analyzing the cleavage of the α′ chain.
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